Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02242032
Other study ID # P-321-101
Secondary ID
Status Completed
Phase Phase 1
First received August 28, 2014
Last updated May 1, 2015
Start date July 2014
Est. completion date March 2015

Study information

Verified date May 2015
Source Parion Sciences
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.


Description:

This is a single-center, dose escalation, randomized, double-masked, placebo-controlled, Phase 1/2a trial designed to evaluate the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye for up to 4-weeks of treatment and up to 8 scheduled in clinic visits. This study will conduct a consecutive dose escalation of the following concentrations of P-321 Ophthalmic Solution given two times a day via ocular instillation: 0.0005% (Cohort 1), 0.0015% (Cohort 2), 0.005% (Cohort 3), and 0.01% (Cohort 4). Up to 48 subjects will be enrolled in four consecutive cohorts. Subjects will be randomized to P-321 Ophthalmic Solution or placebo in a 3:1 ratio.

Safety and tolerability assessments, drug plasma concentrations and drug urine concentrations will be evaluated throughout the study in all cohorts.


Recruitment information / eligibility

Status Completed
Enrollment 53
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Individuals of both genders and any race will be eligible for study participation if they:

1. Provide written informed consent.

2. Are 18 - 80 years of age.

3. Corneal fluorescein staining score =2/15 on the NEI/Industry scale

4. Conjunctival lissamine staining score of = 2/18 on the NEI/Industry scale

5. Schirmer <10mm/5min

6. Are willing and able to follow instructions and can be present for the required study visits for the duration of the study.

7. Female patients of child bearing potential must have a negative urine pregnancy test at Screening and agree to use a medically acceptable form of birth control. Male subjects who are sexually active must be willing to use highly effective contraception (i.e., less than 1% failure rate) during heterosexual intercourse from Day 1 through completion of the study.

8. Have a history of Dry Eye Disease in both eyes supported by a previous clinical diagnosis or have a self-reported history of subjective complaints for at least 4 months prior to Screening, low tear volume, and ocular staining.

9. Have documented history of topical lubricants at least daily or the desire to use topical lubricants in the past 4 months.

10. Have normal lid anatomy

Exclusion Criteria:

- Individuals are not eligible for study participation if:

1. Have anterior segment eye disease except primary dry eye.

2. Patients with an identifiable or suspected secondary dry eye, i.e., a documented or likely systemic, ocular, pharmacologic, post-traumatic, post-surgical, or external cause for dry eye symptoms or ocular surface staining.

3. Patients with current punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction are excluded.

4. Have a history of glaucoma or intraocular pressure (IOP) > 25 mmHg at the Screening Visit (Visit 1) or a history of elevated IOP within the past year prior to Visit 1

5. Contact lenses wear in the previous 30 days or during the Treatment Phase of the study.

6. Use of lid scrubs (including baby shampoos)

7. Known hypersensitivity to the study investigational medicinal product, or formulation excipients, including amiloride or related drugs or allergies to the components of the study drug.

8. Any significant chronic illness that, in the opinion of the Principal Investigator (PI), could interfere with the study parameters.

9. Use of any investigational product or device within 30 days prior to the Screening Visit or during the study.

10. Those unable in the opinion of the PI to comply fully with the study requirements or complete the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
P-321 Ophthalmic Solution

P-321 Ophthalmic Solution placebo
Placebo to match P-321 Ophthalmic Solution

Locations

Country Name City State
United States Sall Research Medical Center Artesia California

Sponsors (1)

Lead Sponsor Collaborator
Parion Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects with adverse events One primary objective of this trial is to assess the safety of P-321 Ophthalmic Solution versus placebo in subjects with moderate dry eye disease at 14 days (Cohorts 1-4) and 28 days (Cohort 4 only). Days 0, 1, 2, 8, 15, 22 and 28 Yes
Primary Changes from baseline in 14 days in visual acuity. Change from baseline at 14 days in visual acuity. Change from baseline at 14 days. Yes
Primary Change from baseline at 28 days in visual acuity for Cohort 4 only. Change from baseline at 28 days in visual acuity for Cohort 4 only. Change from baseline at 28 days in visual acuity. Yes
Primary Changes from baseline at 14 days in corneal staining. Changes from baseline at 14 days in corneal staining. Changes from baseline at 14 days. Yes
Primary Changes from baseline at 28 days in corneal staining for cohort 4 only. Changes from baseline at 28 days in corneal staining for cohort 4 only. Changes from baseline at 28 days. Yes
Primary Changes from baseline at 14 days in conjunctival staining. Changes from baseline at 14 days in conjunctival staining. Changes from baseline at 14 days Yes
Primary Changes from baseline at 28 days in conjunctival staining for Cohort 4 only. Changes from baseline at 28 days in conjunctival staining for Cohort 4 only. Changes from baseline at 28 days Yes
Primary Changes from baseline at 14 days in intraocular pressure. Changes from baseline at 14 days in intraocular pressure. Changes from baseline at 14 days. Yes
Primary Changes from baseline at 28 days in intraocular pressure. for Cohort 4 only. Changes from baseline at 28 days in intraocular pressure. for Cohort 4 only. Changes from baseline at 28 days Yes
Primary Changes from baseline at 14 days in ophthalmoscopy. Changes from baseline at 14 days in ophthalmoscopy. Changes from baseline at 14 days Yes
Primary Changes from baseline at 28 days in ophthalmoscopy for Cohort 4 only. Changes from baseline at 28 days in ophthalmoscopy for Cohort 4 only. Changes from baseline at 28 days Yes
Secondary Measure plasma P-321 concentrations Drug plasma concentrations will be evaluated pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Days 1 and 15 and pre-dose on Day 8. Pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Days 1 and Day 15 and pre-dose on Day 8. No
Secondary Measure urine concentrations of P-321 Drug urine concentrations will be evaluated at Day 1 and Day 15. At multiple timepoints throughout the study No
Secondary Measure tear concentrations of P-321 Drug tear concentrations will be evaluated at all visits post dose. pre-dose 0.5, 1, 2, 4, and 6 hours post dosing on Day 1 and Day 15 and pre-dose on Day 8. No
Secondary Measure plasma P-321 concentrations in Cohort 4 Measure plasma P-321 concentrations in Cohort 4 pre-dose on Day 8 and Day 22, and pre-dose, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose on Day 28 No
Secondary Measure urine concentrations of P-321 in Cohort 4 Measure urine concentrations of P-321 in Cohort 4 Day 28 No
Secondary Measure tear concentrations of P-321 in Cohort 4 Measure tear concentrations of P-321 in Cohort 4 pre-dose on Day 8 and Day 22, and pre-dose, 0.5, 1, 2, 4, 6, 8, and 24 hours post-dose on Day 28 No
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3